[Click eStock] "Boryung, Eli Lilly Obesity Treatment 'Mounjaro' Sales Expectations"

Stunning Value Research analyzed on the 16th that Boryung is expected to co-promote Eli Lilly's obesity treatment drug 'Mounjaro'. No investment opinion or target price was provided.

Namgung Jun, a researcher at Stunning Value Research, said, "Eli Lilly's obesity treatment drug 'Mounjaro', which is attracting global attention, recently received approval from the Ministry of Food and Drug Safety." He added, "Boryung acquired domestic rights for 'Zyprexa', 'Alimta', and 'Gemzar' from Eli Lilly and is currently co-promoting the diabetes treatment drug 'Trulicity'." He continued, "Due to the ongoing business relationship with Eli Lilly, co-promotion of 'Mounjaro', a drug similar to 'Trulicity', is expected."

Boryung's sales and operating profit in the first half of this year were 489.2 billion KRW and 36.5 billion KRW, respectively, representing increases of 16.5% and 4.1% compared to the same period last year. He explained, "Although sales and operating profit in the second quarter were expected to decline due to medical strikes, both slightly exceeded market expectations. Prescription drugs and over-the-counter drugs grew evenly, and the 'Kanab Family' product line achieving the highest half-year sales performance appears to have been a major factor in the increase in first-half sales."